JP6012603B2 - バイオフィルムを除去するための組成物および方法 - Google Patents

バイオフィルムを除去するための組成物および方法 Download PDF

Info

Publication number
JP6012603B2
JP6012603B2 JP2013528356A JP2013528356A JP6012603B2 JP 6012603 B2 JP6012603 B2 JP 6012603B2 JP 2013528356 A JP2013528356 A JP 2013528356A JP 2013528356 A JP2013528356 A JP 2013528356A JP 6012603 B2 JP6012603 B2 JP 6012603B2
Authority
JP
Japan
Prior art keywords
protein
polypeptide
transcription
factor
biofilm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013528356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542185A5 (enExample
JP2013542185A (ja
Inventor
スティーブン ディー． グッドマン，
スティーブン ディー． グッドマン，
ローレン オー． バカレッツ，
ローレン オー． バカレッツ，
Original Assignee
ユニバーシティー オブ サザン カリフォルニア
ユニバーシティー オブ サザン カリフォルニア
ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド
ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー オブ サザン カリフォルニア, ユニバーシティー オブ サザン カリフォルニア, ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド, ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド filed Critical ユニバーシティー オブ サザン カリフォルニア
Publication of JP2013542185A publication Critical patent/JP2013542185A/ja
Publication of JP2013542185A5 publication Critical patent/JP2013542185A5/ja
Application granted granted Critical
Publication of JP6012603B2 publication Critical patent/JP6012603B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A01N37/46—N-acyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dental Preparations (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
JP2013528356A 2010-09-09 2011-09-09 バイオフィルムを除去するための組成物および方法 Active JP6012603B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38137710P 2010-09-09 2010-09-09
US61/381,377 2010-09-09
PCT/US2011/051107 WO2012034090A1 (en) 2010-09-09 2011-09-09 Compositions and methods for the removal of biofilms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015193476A Division JP2016000760A (ja) 2010-09-09 2015-09-30 バイオフィルムを除去するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2013542185A JP2013542185A (ja) 2013-11-21
JP2013542185A5 JP2013542185A5 (enExample) 2014-09-25
JP6012603B2 true JP6012603B2 (ja) 2016-10-25

Family

ID=44654515

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013528356A Active JP6012603B2 (ja) 2010-09-09 2011-09-09 バイオフィルムを除去するための組成物および方法
JP2015193476A Withdrawn JP2016000760A (ja) 2010-09-09 2015-09-30 バイオフィルムを除去するための組成物および方法
JP2017122250A Active JP6420417B2 (ja) 2010-09-09 2017-06-22 バイオフィルムを除去するための組成物および方法
JP2018081136A Withdrawn JP2018111731A (ja) 2010-09-09 2018-04-20 バイオフィルムを除去するための組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015193476A Withdrawn JP2016000760A (ja) 2010-09-09 2015-09-30 バイオフィルムを除去するための組成物および方法
JP2017122250A Active JP6420417B2 (ja) 2010-09-09 2017-06-22 バイオフィルムを除去するための組成物および方法
JP2018081136A Withdrawn JP2018111731A (ja) 2010-09-09 2018-04-20 バイオフィルムを除去するための組成物および方法

Country Status (6)

Country Link
US (2) US20120128701A1 (enExample)
EP (1) EP2613797B1 (enExample)
JP (4) JP6012603B2 (enExample)
AU (1) AU2011299025B2 (enExample)
CA (1) CA2810851C (enExample)
WO (1) WO2012034090A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017160265A (ja) * 2010-09-09 2017-09-14 ユニバーシティー オブ サザン カリフォルニア バイオフィルムを除去するための組成物および方法

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
WO2011123396A1 (en) * 2010-03-29 2011-10-06 University Of Southern California Compositions and methods for the removal of biofilms
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
JP2016521752A (ja) * 2013-06-13 2016-07-25 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
EP3113630B1 (en) 2014-03-06 2019-12-11 The Research Institute at Nationwide Children's Hospital Probiotic formulations and methods for use
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
WO2016154491A1 (en) * 2015-03-25 2016-09-29 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US20180207067A1 (en) 2015-07-14 2018-07-26 Research Institute at Nationwide Children's Hospit al Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
HK1255383A1 (zh) 2015-07-31 2019-08-16 The Research Institute At Nationwide Children's Hospital 去除生物膜的肽及抗體
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
EP3565589A1 (en) 2017-01-04 2019-11-13 Research Institute at Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
WO2018129092A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
BR112019014921A2 (pt) 2017-01-27 2020-03-31 StemRIM Inc. Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica
EP3595445B1 (en) * 2017-03-15 2024-09-04 The Research Institute at Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
EP3719117A4 (en) 2017-12-01 2021-11-03 Stemrim Inc. EECTODERMAL MESENCHYMAL STEM CELLS AND METHOD FOR PRODUCING THEM
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
JP6641420B2 (ja) 2018-06-12 2020-02-05 株式会社アマダホールディングス 分割金型の装着方法及びプレスブレーキ
WO2019241177A1 (en) * 2018-06-12 2019-12-19 Terumo Cardiovascular Systems Corporation Circular retractor for cardiovascular valve procedures
EP3860718A4 (en) 2018-10-05 2022-08-31 Research Institute at Nationwide Children's Hospital HMGB1 PROTEIN DERIVATIVES FOR BIOFILM REMOVAL
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
US12453747B2 (en) 2019-06-03 2025-10-28 Research Institute At Nationwide Children's Hospital Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies
BR112021026890A2 (pt) 2019-07-08 2022-03-15 Res Inst Nationwide Childrens Hospital Composições de anticorpo para interromper biofilmes
WO2025106896A1 (en) * 2023-11-17 2025-05-22 Rush University Medical Center Coating of medical and implant biomaterials with an anti-biofilm agent to prevent and treat infection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US20050131222A1 (en) 1995-04-21 2005-06-16 Human Genome Sciences, Inc. Nucleotide sequence of the haemophilus influenzae Rd genome, fragments thereof, and uses thereof
US6355450B1 (en) 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US20020132753A1 (en) * 2000-01-31 2002-09-19 Rosen Craig A. Nucleic acids, proteins, and antibodies
AU2002367953C1 (en) 2001-05-04 2009-02-19 Paratek Pharmaceuticals, Inc Transcription factor modulating compounds and methods of use thereof
HUP0500042A3 (en) * 2001-05-15 2010-01-28 Long Island Jewish Res Inst Use of hmg fragments as anti-inflammatory agents
EP1421108A2 (en) 2001-08-24 2004-05-26 Micrologix Biotech, Inc. Antimicrobial and anti-inflammatory peptides
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US20030099602A1 (en) 2001-10-25 2003-05-29 Levin Gilbert V. D-tagatose as an anti-biofilm agent
DK2255826T3 (en) 2002-08-02 2016-06-20 Glaxosmithkline Biologicals Sa Neisserial vaccine compositions comprising a combination of antigens.
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
AU2003295653B2 (en) * 2002-11-20 2007-08-16 The Feinstein Institute Of Medical Research Use of HMGB polypeptides for increasing immune responses
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
WO2004061456A2 (de) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
WO2004062583A2 (en) 2003-01-07 2004-07-29 University Of Iowa Research Foundation Vaccine and method for preventing biofilm formation
WO2004072094A2 (en) * 2003-02-14 2004-08-26 Fondazione Centro San Raffaele Del Monte Tabor Hmgb1 modulator binding domain
JP2006519605A (ja) 2003-03-06 2006-08-31 チルドレンズ ホスピタル， インコーポレイテッド 類型不能ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅの中耳炎単離株の遺伝子
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
US20090029929A1 (en) 2004-03-26 2009-01-29 Locomogene, Inc. Decoy Nucleic Acid to Synoviolin Gene Promoter
US20080305120A1 (en) * 2004-06-17 2008-12-11 Medimmune, Inc. Immunogenic Compositions Comprising Hmgb 1 Polypeptides
CA2578478A1 (en) 2004-08-06 2006-02-16 National Jewish Medical And Research Center Product and process for inhibition of biofilm development
WO2007001422A2 (en) 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
US20060228384A1 (en) 2005-04-06 2006-10-12 Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor
WO2006114805A2 (en) * 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
US20090264342A1 (en) 2006-02-13 2009-10-22 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
EP2061886B1 (en) 2006-08-21 2014-05-07 The University Of British Columbia Small cationic immunomodulatory peptides
EP1980269A1 (en) 2007-04-13 2008-10-15 Katholieke Universiteit Leuven Prevention of staphylococcus biofilm formation
WO2011123396A1 (en) * 2010-03-29 2011-10-06 University Of Southern California Compositions and methods for the removal of biofilms
AU2011299025B2 (en) 2010-09-09 2015-07-09 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
JP2016521752A (ja) 2013-06-13 2016-07-25 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017160265A (ja) * 2010-09-09 2017-09-14 ユニバーシティー オブ サザン カリフォルニア バイオフィルムを除去するための組成物および方法

Also Published As

Publication number Publication date
AU2011299025B2 (en) 2015-07-09
JP2018111731A (ja) 2018-07-19
JP6420417B2 (ja) 2018-11-07
EP2613797A1 (en) 2013-07-17
WO2012034090A1 (en) 2012-03-15
CA2810851C (en) 2022-08-02
EP2613797B1 (en) 2015-11-04
US20160095316A1 (en) 2016-04-07
US10595530B2 (en) 2020-03-24
JP2013542185A (ja) 2013-11-21
CA2810851A1 (en) 2012-03-15
US20120128701A1 (en) 2012-05-24
AU2011299025A1 (en) 2013-03-21
JP2017160265A (ja) 2017-09-14
JP2016000760A (ja) 2016-01-07

Similar Documents

Publication Publication Date Title
JP6420417B2 (ja) バイオフィルムを除去するための組成物および方法
JP6728257B2 (ja) バイオフィルムの除去のための組成物および方法
Nielubowicz et al. Host–pathogen interactions in urinary tract infection
JP2022179770A (ja) バイオフィルムの除去のためのペプチドおよび抗体
US20230190908A1 (en) Dnabii vaccines and antibodies with enhanced activity
CN112823038B (zh) 用于移除生物膜的hmgb1蛋白衍生物
JP7661008B2 (ja) バイオフィルム関連障害の処置のための抗体断片
JP2001515467A (ja) モラクセラ・カタラーリスのｕｓｐａ１及びｕｓｐａ２抗原
JP2025122021A (ja) 抗炎症剤
CN114423448A (zh) 疫苗组合物和选择抗原的方法
KR101768118B1 (ko) 기도 감염의 치료를 위한 방법 및 약학 조성물
US20050042690A1 (en) Diagnosis and management of infection caused by chlamydia
CN116096239B (zh) 治疗和预防生物膜的联合疗法
US20210332095A1 (en) Infection-induced endothelial amyloid compositions as antimicrobials
Grousd Defining Staphylococcus aureus Virulence Factors in Bacterial Pneumonia and Influenza Super-Infection
Yang MEMORY TH17 CELLS IN THE LUNG DURING SECONDARY BACTERIAL PNEUMONIA FOLLOWING INFLUENZA A VIRUS INFECTION
Murray A New Class Of Haemophilus Ducreyi? Molecular Characterization Of Samoa Strains Sb 5755, Sb 5756, Sb 5757, And Be 3145
do Nascimento Mil-Homens Burkholderia cenocepacia pathogenesis: unraveling the virulence functions of trimeric
JP2007508837A (ja) 歯周疾患のためのワクチン
Wu Identification and characterization of Porphyromonas gingivalis virulence genes using a pPGIVET system

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160601

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160920

R150 Certificate of patent or registration of utility model

Ref document number: 6012603

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250